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Objective The discrimination of bacterial infections from
sterile inflammatory processes is of great importance in
the management of inflammation. Currently available
techniques cannot decisively address this issue. In this
respect, antimicrobial peptide 99mTc-ubiquicidin (UBI)
29–41 scans have been showing interesting results. The
aim of this study was to determine the accuracy of
99mTc-UBI scan in the detection of osteomyelitis and to
compare it with 99mTc-methylene diphosphonate scan
and magnetic resonance imaging (MRI).
Methods Twenty patients (mean age=48.90 years) with
suspected osteomyelitis were included in this study. After
evaluation of each patient through history taking, physical
examination, appropriate laboratory tests, and other
processes including bone probing, wound culture, and
plain film radiography, MRIs, 99mTc-UBI scans, and
99mTc-methylene diphosphonate scans were performed.
For quantitative analysis, the mean count of abnormal-to-
normal (A/N) region was calculated for images acquired
at 15, 30, 45, 60, 120, and 240min to obtain the most
favorable time for imaging.
Results In total, osteomyelitis was detected in the
99mTc-UBI scans of 17 patients, indicating 100% accuracy,
compared with an accuracy of 90% for osteomyelitis
detected in three-phase bone scans. The maximum
mean A/N was observed at 15min after intravenous
injection (median: 1.91; interquartile range: 1.54–2.94). MRI
was performed in 12 cases only with 75% accuracy. In
addition, the A/N ratios for the 99mTc-UBI scans were not
significantly different between patients with or without
Staphylococcus aureus growth on wound cultures.
Conclusion For fast imaging with high accuracy,
99mTc-UBI 29–41 is a suitable choice for the detection
of osteomyelitis. Nucl Med Commun 32:716–723 c 2011
Wolters Kluwer Health | Lippincott Williams & Wilkins.
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Introduction
The timely and accurate clinical diagnosis of infectious
diseases can be challenging, but is critical to the patient’s
outcome. The presently available radiopharmaceuticals are
often incapable of determining between sterile inflamma-
tion and infection. Many pharmaceuticals labeled with
different radioisotopes, such as immunoglobulins [1,2],
liposomes labeled with 99mTc [3], the avidin–biotin system
[4], antigranulocyte antibodies and antibody fragments,
chemotactic peptides, cytokines, interleukins, platelet
factor 4, and ciprofloxacin labeled with 99mTc [5] have
been used, but an optimal agent has not yet been found.
Thus, autologous leukocytes labeled with 111In or 99mTc-
hexamethylpropyleneamine oxime are still considered the
gold standard despite the practical limitations of consider-
able time and labor for preparation and the necessity of a
sterile environment [6]. The most promising choice is
directly targeting infectious agents with radiolabeled
antibiotics or antimicrobial peptides [7].
In this respect, a number of radiolabeled peptides
have been assessed for the scintigraphic recognition of
infections [8,9]. The most promising ones among them
are 99mTc-labeled cationic antimicrobial peptides origi-
nating from ubiquicidin (UBI), which remarkably bind to
microorganisms [10,11]. These radiolabeled antimicrobial
peptides result in the rapid visualization of Gram-positive
and Gram-negative bacterial infections [12] and fungi
[10], with the least accumulation at sites of sterile
inflammation [11]. Furthermore, 99mTc-UBI 29–41 has
been used to monitor the effectiveness of treatment of
experimental infections in animals [13]. Although results
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from limited preclinical and pilot studies in patients are
promising [14,15], this important agent is not currently
available for routine clinical use. The aim of this study
was to compare the sensitivity and specificity of 99mTc-
labeled UBI scintigraphy with bone scans in the diagnosis
of osteomyelitis. In addition, we had two other objectives:
(a) whenever possible, compare this modality with
magnetic resonance imaging (MRI) and (b) assess the
feasibility of this radiotracer for routine practice.
Materials and methods
Participants
This study was conducted on 20 patients who were
referred to our nuclear medicine department with clinical
suspicion of osteomyelitis, due to diabetic foot ulcers,
inflammation at the site of prosthesis, or bone fractures.
The patients were recruited from a university hospital from
2008 to 2010. Before starting the antibiotic treatment, the
patients first underwent 99mTc-UBI scanning, followed by
three-phase 99mTc-methylene diphosphonate (MDP) bone
scanning with a 4-day interval.
On the primary visit, wound culture and careful physical
examination, including probing and, when possible, bone
biopsy, were performed by infectious or orthopedic
specialists and laboratory staff from the Department of
Infectious Disease at our hospital.
The study complies with the Declaration of Helsinki and
was approved by the Institutional Ethics Committee of
Bushehr University of Medical Sciences; all patients
provided written informed consent.
Imaging protocols
99mTc-ubiquicidin scintigraphy
Scans were performed using a dual-head ADAC camera,
(ADAC Genesys, Malpitas, California, USA) equipped
with a pair of low-energy, high-resolution collimators.
Preparation of 99mTc-UBI entailed adding 740MBq
(20mCi) 99mTc to vials of HYNIC-UBI 29–41 from a kit
[14] (Radioisotope Division, Atomic Energy Organization
of Iran) and incubating for 15min at room temperature.
The average radiochemical purity of 99mTc-HYNIC-UBI
29–41, produced by lyophilized kits, was more than
95%, congruent with a specific activity of 67.6GBq/mmol,
obtained by high-performance liquid chromatography,
instant thin-layer chromatography, and solid-phase ex-
traction. Immediately after intravenous (i.v.) injection
of 740MBq of 99mTc-UBI, dynamic imaging for 60 s for
each frame up to 15min was performed on the suspected
infection area and the contralateral normal region as a
nontarget area. Similarly, whole-body anterior and posterior
projections followed by spot views of the region of
interest (ROI) were also acquired at 15, 30, 45, 60, 120,
and 240min postinjection. An expert nuclear medicine
specialist evaluated projections to optimize the quality
of the images.
Quantitative analysis
Positive 99mTc-UBI scans were further analyzed by
drawing manual ROIs over the suspected abnormal and
contralateral normal bony sites. By selection of ROI
analysis of the manipulation menu of the process menu
in the ADAC software, the entire lesion was included
in the region and mean counts per pixel in each region
were measured. The mean uptake count ratios between
abnormal and contralateral normal sites (A/N) were
also obtained; these indices were acquired from the
reference images.
99mTc-methylene diphosphonate scintigraphy
Bone scans were performed using 740MBq (20mCi) of
99mTc-MDP. The first phase of the bone scan consisted of
a radionuclide angiogram, comprised of sequential images
at 2–3 s per frame over the involved region of suspected
osteomyelitis and the opposite presumed normal ana-
tomic region. The flow phase was carried out for 60 s,
followed by a blood-pool image at 180 s post i.v. injection
of the radiopharmaceutical. Furthermore, 120min post
i.v. injection of the 99mTc-MDP (740MBq), whole-
body bone scintigraphy with multiple spot views was
performed.
All the radionuclide images were read by two nuclear
medicine physicians without knowledge of radiological
and laboratory data.
In the interpretation of the 99mTc-UBI scan, there are
four degrees; score 0 equals soft tissue; score 1, less than
liver uptake; score 2 is more than or equal to liver uptake;
and score 3 is more than or equal to the renal uptake [16].
Infection was considered based on scores of 2 or 3 on the
99mTc-UBI scan [16].
Osteomyelitis was determined based on a significant
uptake of radiopharmaceutical in all three phases of
99mTc-MDP or an accumulation on the 99mTc-UBI scans
as mentioned above (Figs 1 and 2). Remarkable radio-
nuclide uptake on the 99mTc-MDP without significant
uptake on the 99mTc-UBI scan was considered indicative
of aseptic inflammation (Fig. 3).
Magnetic resonance imaging
MRI was performed with l.5-T Signal imager (General
Electric, Milwaukee, Wisconsin, USA) with three spin-
echo pulse sequences emphasizing T1-weighted, T2-
weighted, and fluid-attenuated inversion recovery-weighted
information. The scans and MRI were performed within
a 3-day interval. Plain film radiography (PFR) and MRI
images were interpreted separately by two expert radio-
logists without awareness of the results of scintigraphy and
laboratory tests. On unenhanced images, the MRI criteria
for the presence of osteomyelitis were diminished signal
intensity on the T1-weighted sequences and increased
signal intensity on T2-weighted sequences within the bone
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marrow [17]. After contrast administration, focal abnormal
bone marrow enhancement on fat-suppressed T1-weighted
images was considered as osteomyelitis [17]. When visible
radiographically on PFR, focal bone rarefaction, diminished
bone density, periostitis, bone erosion, or destruction were
considered as osteomyelitis.
Gold standard
The final diagnosis was according to the consensus of
clinicians according to clinical presentation, histopatho-
logic examinations, wound culture, probing, response to
antibiotic therapy, laboratory tests, and clinical follow-up.















There is a significant activity in the left ankle in the early views (1–45 min) of 99mTc-ubiquicidin scintigraphy of a 44-year-old thallasemic male patient
(patient number 4), which persists over the course of the study (up to 240 min; a–c). The whole-body bone scan also shows osteomyelitis in the
same region (d). In addition, osteomyelitis is evident in the tarsal bones as bone marrow hyperintensity on the fat-suppressed T2-weighted magnetic
resonance image (arrow a). There is also a small amount of joint effusion (arrow b), which could be suggestive of concomitant septic arthritis (e).
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There is significant activity in the left metatarsal and left first toe bones in the early views (1–45 min) of 99mTc-ubiquicidin scintigraphy of a 52-year-old
diabetic male patient (patient number 7), which persists over the course of the study (up to 240 min; a and b). The three-phase body bone scan also
shows osteomyelitis in the same region (c). In contrast, the fat-suppressed T2-weighted magnetic resonance image does not indicate osteomyelitis
(d). Pseudomonas aeruginosa was isolated from the wound culture.
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Statistical analysis
The distribution of variables was assessed using prob-
ability plots and the Shapiro–Wilk test, and they were not
fit to a Gaussian distribution. The Mann–Whitney U-test
was applied for the quantitative comparison of A/N ratios
between patients with and without Staphylococcus aureus
(S. aureus) in their wound cultures. The Wilcoxon test was
used for the comparison of A/N ratios in different times.
The images were categorized as true positive (TP), true
negative (TN), false positive (FP), or false negative (FN).
Thereafter, the statistical parameters were determined
as follows: specificity [TN/(TN+FP)], sensitivity [TP/
(TP+FN)], PPV [TP/(TP+FP)], NPV [TN/(TN+
FN)], and accuracy [(TP+TN)/(TP+TN+FN+FP)].
Fig. 3
There is significant uptake of 99mTc-methylene diphosphonate in the left sacroiliac joint of a 20-year-old thallasemic male patient (patient number 1) in
bone scintigraphy (a and b) without significant uptake in the 99mTc-ubiquicidin scan (c), indicating aseptic inflammation.
Table 1 Total outcomes of the scintigraphy studies
Patient number Ulcer location History PFR MRI
Three-phase
99mTc-MDP 99mTc-UBI Gold standard Final diagnosis
1 Sacroiliac joint Thalassemia TN TN FP TN CP, CF, RTT No infection
2 Left ankle DM TN TN TN TN CP, CF, probing, RTT No infection
3 Right medial malleolus Fracture TP TP TP TP WC, biopsy Osteomyelitis
4 Right tibia, Right Femur Fracture FN FN TP TP WC, biopsy, probing Osteomyelitis
5 Left ankle Thalassemia TP TP TP TP WC, biopsy Osteomyelitis
6 Left calcaneus DM FN TP TP TP WC, biopsy, probing Osteomyelitis
7 Left metatarsi, left first toe DM FN FN TP TP WC, probing, biopsy Osteomyelitis
8 Left calcaneus DM TP NA TP TP CP, CF, probing Osteomyelitis
9 Right metatarsi DM TP NA TP TP CP, CF, WC, probing Osteomyelitis
10 Right calcaneus DM TP TP TP TP WC, probing, RTT Osteomyelitis
11 Left metatarsi DM FN TP TP TP WC, probing, RTT Osteomyelitis
12 Left tibia Fracture, prosthesis TP NA TP TP CP, biopsy Osteomyelitis
13 Both tibiae IVDU TP TP TP TP CP, WC Osteomyelitis
14 Sacroiliac joint Bedsore FN NA TP TP WC, probing, biopsy Osteomyelitis
15 Right metatarsi DM FN NA TP TP CP, CF, WC, probing Osteomyelitis
16 Left tibia, left fibula Fracture FN FN TP TP WC, biopsy, probing Osteomyelitis
17 Left metatarsi DM TN TN FP TN Probing, biopsy No infection
18 Right tibia DM FN NA TP TP WC, probing, biopsy Osteomyelitis
19 Left tibia Fracture, prosthesis FN NA TP TP WC, biopsy Osteomyelitis
20 Right tibia DM TP NA TP TP WC, biopsy Osteomyelitis
CF, clinical follow-up; CP, clinical presentation; FN, false negative; FP, false positive; MDP, methylene diphosphonate; MRI, magnetic resonance imaging; OS, orthopedic
surgery; PFR, plain film radiography; RTT, response to treatment; TN, true negative; TP, true positive; UBI, ubiquicidin; WC, wound culture.
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A P value of less than 0.05 was considered to be statistically
significant. Statistical analysis was conducted using an IBM
computer and PASW software, version 18.0 (SPSS, Inc.,
Chicago, Illinois, USA).
Results
The study included 12 men and eight women (mean age,
48.90±15.37 years; range, 20–69 years). Eleven patients
had diabetes mellitus; five patients had fractures and/or
prostheses; two patients had thalassemia; one patient had
a bedsore; and one had a history of drug abuse. From a
total of 20 patients, 17 cases had osteomyelitis and three
cases had aseptic inflammation (Table 1).
None of the patients had any adverse reactions after the i.v.
injection of 99mTc-HYNIC-UBI 29–41, and no side effects
were reported up to 14 days after the administration.
There was a complete agreement between specialists in
interpretations of scans, PFR, and MRI in this study.
For the diagnosis of osteomyelitis, 99mTc-UBI scans
showed 100% (17/17) sensitivity and specificity (3/3).
99mTc-MDP scans showed an excellent sensitivity for the
diagnosis of osteomyelitis, but the specificity was
significantly compromised [100% (17/17) and 33% (1/3),
respectively]. Osteomyelitis could not be differentiated
from aseptic inflammation (Table 2). Even in early views,
99mTc-UBI scans revealed rapid tracer distribution with
higher activity at the site of infection than on the
contralateral healthy side (Fig. 2a).
Furthermore, for quantitative analysis, A/Ns were calcu-
lated for images acquired at 15, 30, 45, 60, 120, and
240min to get the most favorable imaging time. The
maximum A/N ratio was observed at 15min after i.v.
injection (median: 1.91; interquartile range: 1.54–2.94).
In addition, the A/N ratio at 30min was 1.84, 1.65–2.57;
45min, 1.82, 1.70–2.64; 60min, 1.81, 1.70–2.28; 120min,
1.78, 1.45–2.06; and at 240min, it was 1.53, 1.36–1.89.
There are significant differences among A/N ratios of the
early views in comparison with delayed views at 240min
(P value <0.05). The A/Ns for all patients at the
different times are compared in Fig. 4.
Similarly, wound culture was performed on 15 patients.
Bacterial growth was reported in 11 cases: Gram-negative
bacterial infection was found in three cases and mixed or
pure S. aureus was isolated from the eight remaining
participants. Specifically, S. aureus, Escherichia coli (E. coli),
Klebsiella pneumonia, Pseudomonas aeruginosa, Staphylococcus
epidermis, and Acinetobacter were reported. In comparisons
of the patients according to the presence or absence of
S. aureus infection in their wound cultures (Table 3), the
A/N indices were not significantly different at early and
delayed views over the course of the study on 99mTc-UBI
scans (P>0.05).
PFR had 47% (8/17) sensitivity and 100% (3/3) specificity
for osteomyelitis detection as diagnosed by the gold
standard. On account of metallic prostheses or, in some
cases, the patient’s refusal, MRI was taken in only 12
cases, resulting in 66.66% (6/9) sensitivity and 100% (3/3)
specificity and three FN cases (Fig. 2). In 11 diabetic
patients, MRI also resulted in one FN case, whereas the
99mTc-UBI scan was accurate in all of them.
Statistical analysis revealed an accuracy of 100% (20/20)
for 99mTc-UBI scintigraphy, 90% (18/20) for 99mTc-MDP
scintigraphy, 75% (9/12) for MRI, and 55% (11/20) for
radiograph (Table 2).
Table 2 The statistical values of different modalities in detection of
osteomyelitis
PFR MRI (12 case)
Three-phase
99mTc-MDP 99mTc-UBI
Sensitivity (%) 47 (8/17) 66.66 (6/9) 100 (17/17) 100 (17/17)
Specificity (%) 100 (3/3) 100 (3/3) 33 (1/3) 100 (3/3)
PPV (%) 100 (8/8) 100 (6/6) 89 (17/19) 100 (17/17)
NPV (%) 25 (3/12) 50 (3/6) 100 (1/1) 100 (3/3)
Accuracy (%) 55 (11/20) 75 (9/12) 90 (18/20) 100 (20/20)
MDP, methylene diphosphonate; MRI, magnetic resonance imaging; NPV,
negative predictive value; PFR, plain film radiography; PPV, positive predictive
value; UBI, ubiquicidin.
Fig. 4




















The median and interquartile ranges of the abnormal-to-normal (A/N)
ratios in different time images during 99mTc-ubiquicidin scintigraphy.
There are significant differences among A/N ratios of the early views in
comparison with delayed view at 240 min (P< 0.05).
Table 3 The comparison of abnormal-to-normal ratios between
patients with and without Staphylococcus aureus in their wound







15 1.80 (1.64–3.23) 1.93 (1.43–2.33) 0.83
30 1.84 (1.68–2.57) 2.00 (1.28–2.29) 0.68
45 1.77 (1.70–2.55) 2.00 (1.28–2.40) 0.83
60 1.78 (1.70–2.32) 2.00 (1.24–2.22) 0.87
120 1.78 (1.40–1.86) 1.60 (1.20–2.10) 0.68
240 1.51 (1.33–1.58) 1.44 (1.30–1.96) 0.75
The data were expressed as median, interquartile range.
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Discussion
Anatomical imaging modalities are often inappropriate for
the early detection of infection because such techniques
are focused only on morphological changes [10,18],
whereas nuclear imaging can easily detect an inflamma-
tory process because it is based on functional processes,
which are morphologically indistinguishable [19]. In view
of this, infection is usually accompanied by inflammation; it
is much more valuable to make a distinction between
infection and inflammation. In the quest for this distinction,
a broad range of radiopharmaceuticals has been sug-
gested. Radiolabeled leukocytes and gallium-67-citrate
are the most frequently applied radiopharmaceuticals
[20]. However, there is continuous investigation into new
radiopharmaceuticals that allow fast and precise detec-
tion of lesions without the drawbacks of the presently
used radiotracers that require arduous and sophisticated
preparation and present contamination risks [21]. Radio-
labeled monoclonal antibodies in opposition to outside
antigens of granulocytes have the risk of induction of
human antimouse antibodies [22]. In addition, antibody
fragments, interleukins, and platelet factor 4 have certain
limitations [5]. Cytokines and chemotactic peptides are
immunogenic and cytotoxic [23]. There are conflicting
results regarding radiolabeled ciprofloxacin against micro-
organisms responsible for infection [24,25]. Although
positron emission tomography (PET)-computed tomo-
graphy using 18F-fluorodeoxyglucose (FDG) may be promis-
ing for imaging bone infections [26–28], the impact of
elevated serum glucose levels, present mainly in diabetic
patients, on PET sensitivity is a controversial issue [29]. In
addition, its high charge and limited accessibility hinder its
widespread use in the detection of osteomyelitis.
However, from the earliest gallium-67-citrate imaging
to the latest 18F-FDG PET imaging, the main question
has not been satisfactorily answered [15,18]. In all
radiopharmaceuticals, antimicrobial peptides that attach
directly to bacteria are preferred over pharmaceuticals
that have an indirect approach (such as binding to
leukocytes or antigranulocyte antibodies) [22]. Among
the peptides, 99mTc-UBI 29–41 scans have shown the
most promising results for differentiation between
infection and inflammation in animal models [11,12,30]
and also in limited human studies [22].
In this study, the sensitivity, specificity, and overall
diagnostic accuracy of 99mTc-UBI 29–41 scans for the
detection of osteomyelitis were 100%. To our knowledge,
this is the first clinical study to compare 99mTc-UBI scan
with conventional modalities in the detection of osteo-
myelitis in humans. In other studies conducted by
Melendez-Alafort et al. [31] and Becker and Meller
[18], 100% sensitivity and specificity were also shown,
whereas in another study by Akhtar et al. [22], the
sensitivity and specificity values were 100 and 80%,
respectively. In a small study, in seven patients with the
same method of preparation and labeling, 99mTc-UBI also
showed 100% accuracy in osteomyelitis detection [14].
Recently, in a study of 196 patients with fever of
unknown origin, specificity for discrimination between
sterile inflammation and infection was 95.35%, sensitivity
was 97.52%, and accuracy was 96.62% [15]. In addition,
another study showed that the 99mTc-UBI 29–41 scan is a
promising agent for the specific detection of infections in
humans because of its high sensitivity (96.3%), specificity
(94.1%), and accuracy (95.3%) [32].
Therefore, 99mTc UBI 29–41, without accumulation in
sterile inflammation and lack of immunological adverse
effects, may be considered an alternative for leukocyte
labeling, which is still used as the gold standard for
infection detection in nuclear medicine and it is
applicable in leukopenic patients. In another study, it
was shown that 99mTc-UBI (29–41) accumulation directly
draws parallels with the number of viable bacteria and it
can be used for monitoring efficacy and duration of
antibiotic treatment [16].
In this study, the maximum contrast (A/N ratio) was
obtained 15min after 99mTc-UBI administrations, as
previously mentioned [14,22]. These data may suggest a
first pass-like distribution with strong avidity of the tracer
in the direction of its targets, facilitating image interpreta-
tion to distinguish infection as early as 15min postinjection.
In this (Fig. 2b) and previous human studies, 99mTc-UBI
29–41 scans expressed rapid concentration to the target
region and fast renal clearance with negligible liver uptake
and hepatobiliary excretion [14,22,31].
Akhtar et al. [7] revealed that 99mTc-UBI 29–41 had less
avidity at sites infected with E. coli than S. aureus. They
suggested that the lower accumulation with E. coli compared
with S. aureus may be due to either a lower virulence of the
bacterial strain or a diminished affinity of the peptide for
the bacterial membranes. In contrast, our study did not
show any significant difference between those sites infected
with S. aureus and those not infected. Multiple factors may
be responsible for this result, such as not using a wide range
of culture media for growth of anaerobic bacteria and fungi,
and the fact that most of the wound cultures in this
investigation contained mixed growth.
On the basis of these observations, the investigators
suggested that 99mTc-UBI 29–41 could be used for the
detection of infections in humans. Mele´ndez-Alafort et al.
[31] evaluated the use of 99mTc-UBI 29–41 scans as an
infection imaging agent in six children suspected of
having bone infection, and compared with 67Ga scanning,
concluded that 99mTc-UBI 29–41 could be used for the
detection of infections in humans [31]. In a similar study
in 18 adult [22] patients who participated in the trial, 14
were positive for infection as determined with the use of
99mTc-UBI 29–41 scans. The investigators concluded that
99mTc-UBI 29–41 is an effective agent for the imaging of
infection [22].
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In general, the diagnosis of musculoskeletal infection
and osteomyelitis can be clinically challenging in practice.
Infected foot ulcers in the diabetic patient comprise up
to 90% of pedal osteomyelitis cases [33]. Devillers et al.
[34] studied 56 diabetic foot ulcers in 40 patients, and
reported that the accuracy of radiography, 99mTc-MDP,
and 99mTc-hexamethylpropyleneamine oxime-conjugated
leukocyte scintigraphy was 69.6, 62.5, and 92.9%, respec-
tively. They suggested that leukocyte-labeling scintigra-
phy can be considered the gold standard technique for
the identification of osteomyelitis in the diabetic foot.
Although it is accurate, leukocyte-labeling scintigraphy
accompanying bone marrow scan is doomed due to
inaccessibility, labor intensity, and the risk of contamina-
tion [35]. In addition, bone scan can be a sensitive
method for the diagnosis of osteomyelitis. However, it
does not discriminate diabetic osteomyelitis from other
osteoarthropathic conditions due to higher bone turnover
in both conditions [36].
Moreover, based on the literature, MRI can efficiently
discriminate soft tissue infection from bone involve-
ment. It can also effectively detect the development of
infection in anterior parts of the bone. However, its
efficacy is dramatically compromised at the mid foot and
hind foot [33,37–39]. Despite its high sensitivity, MRI
application for the recognition of osteomyelitis in the
diabetic foot is compromised due to lower specificity
related to Charcot neuropathic osteoarthropathy. In addi-
tion, if there is inflammatory hyperemia, the diagnostic
accuracy is further hampered to 40–50% [40]. In a recent
study by Bae et al. [41] in 35 cases, three-phase bone
scans showed a sensitivity of 83% (5/6), specificity of 93%
(27/29), positive predictive value (PPV) of 71% (5/7), and
negative predictive value (NPV) of 96% (18/27) in the
diagnosis of osteomyelitis. MRI showed sensitivity of 83%
(5/6), specificity of 93% (27/29), PPV of 71% (5/7), and
NPV of 89% (24/27) in the diagnosis of osteomyelitis. In
another study of 110 consecutive patients with diabetic
foot, FDG-PET had sensitivity, specificity, PPV, NPV, and
accuracy of 81, 93, 78, 94, and 90%, respectively. MRI
soundly assessed osteomyelitis in 20 of 22 patients and
properly excluded it in 56 of 72 patients, with sensitivity,
specificity, PPV, NPV, and accuracy of 91, 78, 56, 97, and
81%, respectively. PFR also had sensitivity, specificity,
PPV, NPV, and accuracy of 63, 87, 60, 88, and 81%,
respectively [28].
In the participants in our study, MRI accuracy was 75%; we
had three FN results, which may have been due to our
specific population. This study shows that 99mTc-UBI
imaging could be a promising modality in diabetic patients
and cases in which MRI is contraindicated. However, in a
meta-analysis of 16 studies, MRI was shown to be superior
to radiographs, white blood cell scanning, and three-phase
bone scans. Therefore, we recommend further evaluation
of our comment in a larger study [42].
Although our study demonstrates good insight into using
99mTc-UBI compared with 99mTc-MDP and MRI in
osteomyelitis assessment, it should be noted that it has
some shortcomings. The major limitations are the
relatively small sample size with different underlying
problems and the absence of bone biopsy in all patients as
a gold standard test, both of which may have influenced
the results of this study. However, we did consider
compound clinical presentation, histopathologic examina-
tions, and follow-up evaluation to mitigate this deficiency.
Our results should be validated in a larger and well-
designed study.
Conclusion
In summary, 99mTc-UBI 29–41 scans can be applied to
detect bone involvement in infection with excellent
sensitivity and specificity in distinguishing between
infection and inflammation in early views. These data
also showed that the use of 99mTc-UBI in osteomyelitis
studies might lead to images comparable with MRI;
however, further studies are recommended.
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